key: cord-1031782-lprhe8l1
authors: Pocino, Krizia; Napodano, Cecilia; Gragnani, Laura; Ciasca, Gabriele; Colantuono, Stefania; Marri, Silvia; Vantaggio, Lorenzo; Gulli, Francesca; Lorini, Serena; Barini, Antonella; Stefanile, Annunziata; Miele, Luca; Casato, Milvia; Zignego, Anna Linda; Rapaccini, Gian Ludovico; Marino, Mariapaola; Visentini, Marcella; Basile, Umberto
title: Revealed the mystery of HBV related mixed cryoglobulinemia: potential biomarkers of disease progression
date: 2021-02-16
journal: Rheumatology (Oxford)
DOI: 10.1093/rheumatology/keab157
sha: 57f1fe283a73bfe25f5b90e79df838ca60c6fd6c
doc_id: 1031782
cord_uid: lprhe8l1

OBJECTIVES: The biomarkers of an immunological dysregulation due to a chronic Hepatitis B virus (HBV) infection are indeed understudied. If untreated, this condition may evolve into liver impairment also co-occurred by extrahepatic involvements. Here, we aim to identify a new panel of biomarkers including IgG subclasses, Rheumatoid Factor (RF), and Free Light Chains (FLC) that may result useful and reliable for clinical evaluation of HBV-related cryoglobulinemia. METHODS: We retrospectively analyzed clinical data from 44 HBV positive patients. Patients were stratified on the presence/absence of mixed cryoglobulinemia in two group: 22 with cryoglobulins (CGs) and 22 without CGs. Samples from 20 healthy blood donors (HD) were used as negative controls. Serum samples were tested for IgG subclasses, RF (IgM, IgG, and IgA type), and FLC. RESULTS: We detected a strikingly different serum IgG subclasses distribution between HD and HBV positive patients together with different RF isotypes; FLC were significantly increased in HBV-patients if compared with HD while no significant difference was shown between HBV with/without MC. CONCLUSION: The immune-inflammatory response triggered by HBV may be monitored by a peculiar profile of biomarkers. Our results open new perspective in precision medicine era; in these challenging times, they could be also employed to monitor the clinical course of COVID-19 patients, at high risk of HBV reactivation due to liver impairment and/or immunosuppressive therapies.

HBV, an enveloped, partially double stranded DNA virus, chronically infects 350-400 million of the world population with a higher prevalence in the Indian sub-continent, sub-Saharan Africa, and Central Asia although the vaccination program reduced the global prevalence [1] .

Untreated chronic HBV infection can progress to end-stage liver disease, such as cirrhosis and hepatocellular carcinoma (HCC). Liver damage caused by HBV infection is mediated by the immune responses towards the active viral replication [2] . Together with a progressive liver impairment, HBV infection causes a variety of extra hepatic manifestations. In some patients, HBV can trigger a systemic necrotizing vasculitis, e.g. polyarteritis nodosa, with the presence of HBsAg and anti-HBs antibody immune complexes in the vascular lesions [3, 4] ; moreover, a systemic cryoglobulinemic vasculitis (CV) has been described in approximately 3% of HBV patients, mostly affecting the skin, peripheral nervous system and kidney [5] [6] [7] .

CV is the symptomatic manifestation of a condition called mixed cryoglobulinemia (MC), characterized by the presence of circulating cryoglobulins (CGs) consisting in immunoglobulins (Igs) that precipitate at cold temperature, and are usually classified in three subsets. In types II and III, CGs are immune complexes composed generally by polyclonal IgGs, the antigen(s), and monoclonal or polyclonal IgMs, respectively, while type I consists of only monoclonal Ig and it is therefore named as cryoglobulinemia [8] . The IgM commonly display rheumatoid factor (RF) activity, against polyclonal IgG [9] . Types II and III CGs, associated with chronic viral infections (HBV and HCV), can cause a clinically evident CV that may evolve towards a frank B cell lymphoma [10] . Although the association of CV with HCV-chronic infection is stronger, the ex adiuvantibus criterion, showing regression of cryoglobulinemic vasculitis after successful antiviral treatment in HBV patients, clearly confirm the pathogenetic relationship with this virus [5, [11] [12] [13] .

Also, different meta-analyses showed that HBV-infected patients displayed a two-up to threefold higher risk of developing B cell non-Hodgkin lymphomas. Although the HBV pathogenetic contribution to lymphomagenesis is still unknown [14] , pathways common to those described for HCV-induced CV may be involved; in particular, the role of a B-cell populations producing polyclonal cryoglobulins and the subsequent positive selection of B-cells releasing monoclonal cryoglobulins has been postulated [15] .

The natural history of pandemic coronavirus disease 19 (COVID-19) may across HBV infection. IL-6

represents the major pleiotropic cytokine that sustains, through transsignaling mechanism, chronic inflammation towards any injured tissue [16, 17] . It has been reported that IL-6 receptor antagonists employed in COVID patients to control the cytokine storm syndrome unfortunately increase the risk for patients with active or past HBV infection [18] . In consideration of this perspective occurred in COVID patients together with the wide spectrum of worsening outcomes related to HBV infection, it is apparent why reliable circulating immunological biomarkers of viral reactivation and for monitoring therapy and follow-up are widely desired.

It has been reported that chronic HBV-patients display high levels of RF and low C3 levels [19] , suggesting a possible role of HBeAg-antibody complex in the production of RF [20] . Taking in account that the RF is higher in patients with persistent HBsAg positivity than in patients who underwent seroconversion, it was suggested that individuals with abnormal RF are those who failed to clear the virus [21] . Thus, indirectly, RF could represent the marker of a less efficient immune response; moreover, HBV load is associated with RF titer and HBV vaccination may decrease the risk of RF formation [21] .

Light chains of Igs are produced in excess of heavy chains during the synthesis of intact Ig and may enter the bloodstream as free light chains (FLC); increased circulating levels of FLC reflect polyclonal B-cell activation, and determination of serum FLC has become a useful diagnostic tool in immunopathological conditions as they monitor systemic and organ specific autoimmune disease [22, 23] ; in course of HCV-related cryoglobulinemic vasculitis, it represents a surrogate marker for measuring disease and monitoring the possible evolution in B-cell lymphoma [24, 25] .

Most of the auto-abs are class G Ig (IgG), which includes 4 subclasses (IgG1-4). Only recently, serum IgG profile has been described with distinct patterns in different autoimmune disorders, suggesting that different subclasses could be specific for the underlying driving autoantigens [26, 27] .

Here, we aim to validate a new panel of biomarkers for HBV infection, including RF, FLC and IgG subclasses profile that may improve the monitoring of infection worsening outcomes, towards HBVrelated cryoglobulinemia.

This study retrospectively analyzed sera and clinical data from 44 HBV positive patients (age range Table 1 . All serological determinations were performed in our institution's laboratories (Fondazione Policlinico Universitario "A. Gemelli" I.R.C.C.S., in Rome). We also collected and tested serum samples from 20 healthy blood donors (HD) age-and sex-matched as negative controls (age range 35-60 years, mean 52).

Patients were included in the study according to the following criteria: presence of HBV-DNA in serum; absence of HIV co-infection; absence of antiviral treatment and/or immunosuppressive therapy, presence/absence of CGs, presence of MC symptoms in patients with CGs positivity, according to the classification criteria for MC as proposed by the Italian Group for the Study of Cryoglobulinemias in 1989 and later revised in 2002 [5, 28] .

Serum samples were tested for RF (IgM, IgG, and IgA type), IgG subclasses (IgG 1-4) and free k and λ chains. RF level was determined by means of ELISA kits for IgG, IgA and IgM (Menarini, Italy); according to the manufacturer the cutoff is <20 U/mL. According to Clinical and Laboratory Standards Institute (CLSI) guidelines, we tested 20 HD from the local population to verify adherence to CLSI EP 28A3C [29, 30] . Samples were thawed only once and immediately assayed in a single batch, following the manufacturer's instructions. All the determinations were performed by an operator without knowledge of the clinical information of the handled sample. Each sample was tested twice to minimize eventual discrepancies, and all tests were performed in the same laboratory with the same instruments.

The ethic committee of our institution (Università Cattolica del Sacro Cuore, Fondazione Policlinico Universitario "A. Gemelli" I.R.C.C.S.) approved the study (ID: 2080). All patients gave written informed consent to the use of their clinical and serological data in this study. The whole study was conducted according to the Declaration of Helsinki, as revised in 2013.

Statistical analyses were performed using the software package R (3.5.2 release) [31] . Biomarkers were tested for normality by means of a visual inspection of the QQ-Plot, followed by a Shapiro-Wilk test. It was found that some parameters deviate significantly from normality. Patients were divided in two groups based on the presence of CGs. Comparisons between groups was performed with the Wilcoxon Unpaired Two-Sample test. The diagnostic performances of the investigated serum markers in distinguishing HBV patients with and without CGs was assessed by logistic regression and ROC curves. Logistic regression is executed using the function glm from the R package stats to extract probabilities from the fitted models, either with a single biomarker or with several biomarkers used in combination. ROC curves and AUC values were calculated as described in references 32 and 33, using the R package pROC [34] . A forward-backward stepwise logistic regression was used to select the best subset of markers according to the Aikake Information Criterion (AIC). The optimal cut-off is calculated by maximization of Youden's statistics J = sensitivity+specificity-1 [35] . The logistic classifier was validated with the leave-one-out approach using the R function cv.glm. Correlation between variables were evaluated calculating the Spearman's correlation coefficients. Strength of correlation was judged using correlation coefficients of >0.70 as strong correlation, 0.30-0.70 as moderate correlation and <0.3 as weak correlation. Correlation heat maps were calculated with the package corrplot implemented in the software R [36] .

Original data are available upon request to the corresponding author.

A total of 64 subjects were recruited for the study: 44 HBV-positive patients (age range 47-80 years, mean 63) and 20 HD (age range 35-60 years, mean 52) as negative controls; 22 out of 44 HBV patients were diagnosed with MC (Table 1 ).

In Figure 1 , a box-plot analysis of the biomarkers serum levels is shown for HD (cyan) and HBV patients with and without CGs (gold). Comparison between two groups is carried out with the Wilcoxon Unpaired Two-Sample test. P-values are reported in each plot. Significantly raised marker levels were found in HBV patients for RF-IgA (p=3.2e-6), free k (p=0.00081), free λ (p=1e-5) and RF-IgG (p=2.5e-8). A significant reduction in IgG2 levels was measured in HBV patients (p=0.033).

In Figure 2 , a box-plot analysis of the biomarkers serum levels is shown for HBV patients with CGs (cyan) compared to those without CGs (gold) with similar results in the two groups. A statistically significant difference can be found only for IgG3 levels. The direct comparison of these two groups with the Wilcoxon Unpaired Two-Sample Test showed a significant reduction (p=0.031) in the IgG3 levels of patients with CGs.

This analysis suggests that the presence of CGs cannot be inferred starting from the knowledge of one single biomarker, and a more complex model is needed. This conclusion is confirmed in Figure   3a , where a ROC curve analysis is shown for all the investigated parameters separately. Small areas under the curve are measured, with the 95% confidence intervals (CI) often containing the value 0.5, which corresponds to a random classifier. The following AUCs were measured: 0. 

To find a predictive model able to distinguish HBV patients with and without CGs, a stepwise logistic regression in both directions was performed taking into account all the investigated biomarkers.

This analysis was aimed to select the most suitable subset of biomarkers, which minimize the Aikake Information Criterion (AIC).

The procedure selected four out of ten parameters, namely RF-IgM, RF-IgA, IgG3, and FLC λ. In Figure 4 a,b,c) . Nevertheless, a subset of these couples of variables displays sufficient regularity for taking into consideration a regression line to establish a mathematical relationship between the two variables. These scatter plots are highlighted using a gray background. Data are summarized in Table 2 .

The major pathogenetic mechanism for determining cryoglobulinemia consists in the production of aberrant autoantibody by dysregulated B-cells; a chronic inflammatory stimulus could promote this worsening evolution interfering with normal B cell function. CGs are associated with systemic autoimmune diseases, lymphoproliferative disorders, and chronic infections, and above all, HCV

infection. An association of cryoglobulinaemia with chronic HBV infection has been suggested in only ~2% of cases of cryoglobulinemic vasculitis [37] . A worsening evolution towards cryoglobulinemic complications depends on viral-triggered chronic immune stimulation, resulting in an immune dysfunction with the production of polyclonal, oligoclonal, or monoclonal auto-immune complexes, probably due to the molecular mimicry of virus with the target auto-antigens [38] .

Genetic and/or environmental cofactors can have a role in the formation of specific IgG subclasses as a trigger of cryoglobulinemic mechanism, independent by infection. In HCV-related MC, it is still debated if viral infection represents a simple triggering factor or whether it also contributes to the self-perpetuating mechanism of multifactorial and multistep disease process [39] .

A possible role of HBV infection in the pathogenesis of MC has been postulated also confirmed by the evidence of a relationship between undetectable HBV-DNA and regression of MC after antiviral therapy [5, 11, 12] . A wide broad spectrum of serum biomarkers has been deeply analyzed to follow the progression of extra-hepatic disorders in patients with HCV-related MC [9, [40] [41] [42] [43] , instead, in our opinion, biomarkers of HBV-vasculitis have been less investigated.

Our population of HBV-MC patients show high CGs in serum, low levels of complement components (data not shown) and clinical evidence of purpura, peripheral neuropathy, renal involvement, and lymphoproliferative disorders. Our results show a strikingly different serum IgG subclasses distribution was detected between healthy donors and HBV positive patients. This profile might help to understand hyper-stimulation of the immune system by infectious agents, such as viruses, and the chronic inflammatory response can lead to the development of some disorders with loss of control of B and T cells. To sustain a complete and effective immune response, B and T lymphocytes cooperate in a loop in which they affect each other: the disruption of this cross talk profoundly impairs immunological responses and regulation [44] . The specific IgG subclasses profile depends on the type of antigen and on duration of antigen exposure, reflecting a probable specific driving viral surface antigen. Serum levels of IgG subclasses could correlate with the amount of circulating antibody, suggesting a direct relationship between the elevated IgG subclass and the disease process [26] . In a precedent paper, we reported that the early identification of IgG3 RF in sera from HCV-positive patients could represent a biomarker predictor of the development of MC [38] . Here, we did not find a statistically significant difference between HD and HBV patients (p=0.22, Figure 1) confirming that IgG subclasses display a different distribution in different clinical settings [23, 26, 40] .

Comparing the different RF isotypes (IgM, IgA, and IgG) that we found between HD and HBVpositive patients, high levels of RF IgG and RF IgA emerged in HBV patients as expected. This data represents a possible physiological response induced by antibody antigen binding.

to an antigen and Toll-like receptor stimulation by an epitope, which is sustained by their interaction with immune complexes attributed, at least in part, to non-specific liver damage [45] .

RF IgA is present in synovial fluid of patients with Rheumatoid Arthritis and its clinical importance is in predicting response to biological drug [46] . We hypothesize that RF IgA in the setting of HBV could represent a link between autoimmune responses with autoantibodies production, despite until now the interplay of RF with HBV has not been demonstrated.

In Figure 2 we show the trend of RF IgG, IgA, and IgM, higher in HBV-related MC patients then in patients without CGs. These differences are not statistically significant reflecting that, probably, that the same pathogenetic mechanism determines both conditions. The ROC analysis and the Spearman correlation's coefficient among different biomarkers are shown in Figure 3 and 4 respectively. Nevertheless, it can be qualitatively observed that data of patients with CGs have the tendency to be more dispersed than the ones of patients without CGs. This tendency is interesting and deserves a more in-depth study.

Increased FLC levels can be detected in patients suffering from different immunological disorders, suggesting that serum FLC could be a useful biomarker in immunopathological conditions as they reflect polyclonal B-cell activation [22, 47] . The biology of FLC provides evidence for their role in several inflammatory and immune diseases [47] . The assessment of total and antigen specific FLC might be of primary interest and indicate a causal role in several diseases. Their measurement may be useful as a diagnostic marker of co-morbidities and as potential prognostic marker [48] . Our results show high levels of FLC in HBV-positive patients, with a significant difference in comparison to HD while no significant difference was shown between HBV with/without MC.

Biochemical structural differences of pathological FLC could be involved and probably the production of different FLC isotypes by B-lymphocytes could be connected to any still unknown pathways. So, increasing FLC levels could exist in both HBV groups but with different immunochemical features. We could hypothesize that in patients with HBV related MC the FLC could participate in CGs formation phenomenon by stimulating specific B cells.

Reactivity against specific virus antigens would identify the presence of circulating CGs representing first step of activation of B lymphocyte clones, which show a sub-clinical self-reactivity that is not yet symptomatic. The antigenic stimulus leads to formation of Ig autoantibodies that in some cases also exhibit RF activity towards virus-related Ig. The next step leads to the formation of symptomatic CGs with the presence of RF IgM and possible clinical symptoms. HBV viruses is wellrecognized causes for chronic hepatitis, cirrhosis, and even for hepatocellular carcinoma.

The definition of a reliable biomarkers panel represents a very important goal in precision medicine era, to detect any disease at an early stage when it is still curable; in HBV setting, the employment of a biomarker panel including RF, FLC, IgG subclasses could be useful to better stratify immune complex disease in chronic HBV patients improving early diagnosis of HBV-related vasculitis, and ameliorate prognosis paving the way for a tailored-patient better therapy. Last, but not the least, a thin red line joins the worldwide breakdown due to the novel coronavirus disease and the urgent need of reliable biomarkers of immunological state in chronic HBV patients. In COVID-19 patients, an increased risk of HBV reactivation may be correlated to the immune dysfunction associated with liver impairment and/or immunosuppressive therapies employed to control hyper-inflammatory conditions [49] . In the setting of different studies that are ongoing in HBV-positive patients affected by COVID-19 to validate Diacerein as new active metabolite for the inhibition of inflammosome pathways but maintaining anti-HBV properties, immunological reliable biomarkers of HBV activity could play a central role [50] .

Overall, in the spectrum of HBV-related extrahepatic manifestations sometimes with significant morbidity and even mortality in limited cases, for the management of HBC-chronic infected patients with different co-morbidities, serological biomarkers may play a strategical role, but in our opinion still understudied. Our major goal was to conduct an analytic study on serum levels of RF, FLCs and IgG subclasses in a population of HBV-patients. It is worth pointing out that, due to the relatively small number of patients recruited for this study, equation 1 has to be considered a preliminary estimation and the validity of the model and the robustness of its logistic weights have to be confirmed in a further study carried out on a larger sample size. 

Hepatitis B. In: StatPearls

Treasure Island (FL): StatPearls Publishing

Immunopathogenesis of Hepatitis B Virus

Polyarteritis nodosa: A contemporary overview

Immune complexes of hepatitis B surface antigen in the pathogenesis of periarteritis nodosa

Hepatitis B virus related cryoglobulinemic vasculitis: A multicentre open label study from the Gruppo Italiano di Studio delle Crioglobulinemie -GISC

Hepatitis B virus genotypes and extra-hepatic manifestations

Hepatitis B-related autoimmune manifestations

Biologic and clinical significance of cryoglobulins. A report of 86 cases

Different biochemical patterns in type II and type III mixed cryoglobulinemia in HCV positive patients

Cryoglobulins: putative effectors of adaptive immune response

Telbivudine in treatment of hepatitis B-associated cryoglobulinemia

HBV-associated cryoglobulinemic vasculitis: remission after antiviral therapy with Entecavir

Entecavir to treat hepatitis B-associate cryoglobulinemic vasculitis

Hepatitis B infection increases the risk of non-Hodgkin lymphoma: a meta-analysis of observational studies

Cryoglobulinemia: An update in 2019

IL-6, monocyte infiltration and parenchymal cells

trans-signaling through thrombin-induced soluble IL-6 receptor release by platelets

Low risk of hepatitis B reactivation in patients with severe COVID-19 who receive immunosuppressive therapy

Online ahead of print

High Level of Rheumatoid Factor is Associated with Hepatitis B Viremia in Patients with Chronic Hepatitis B

An investigation on rheumatoid factor of different immunoglobulin classes in hepatitis B virus carriers

Analysis of rheumatoid factor according to various hepatitis B virus infectious statuses

Free Light Chain Profile in Myasthenia Gravis Patients

Biomarkers of minimal residual disease in rituximab-treated patients with mixed cryoglobulinemia

Biomarkers in HCVrelated mixed cryoglobulinemia patients withnon-Hodgkin lymphoma

Immunological Role of IgG Subclasses

Long-Lasting Rituximab-Induced Reduction of Specific-But Not Total-IgG4 in MuSK-Positive Myasthenia Gravis

EP05-A3 evaluation of precision of quantitative measurement procedures: approved guideline

Defining, establishing, and verifying reference intervals in the clinical laboratory: approved guideline

R: A Language and Environment for Statistical Computing

A fully-automated neural network analysis of AFM force-distance curves for cancer tissue diagnosis

Nano-mechanical signature of brain tumours

pROC: An open-source package for R and S+ to analyze and compare ROC curves

Index for rating diagnostic tests. Cancer

Visualization of a Correlation Matrix. R Packag v 084

Mixed cryoglobulinemia: demographic, clinical, and serologic features and survival in 231 patients

IgG3 subclass: A possible trigger of mixed cryoglobulin cascade in hepatitis C virus chronic infection

Sentinel biomarkers in HCV positive patients with mixed cryoglobulinemia

Serological profile of asymptomatic HCV positive patients with low level of cryoglobulins

Autoimmunity and lymphoproliferation markers in naïve HCV-RNA positive patients without clinical evidences of autoimmune/lymphoproliferative disorders

Assessment of free light chains in HCV-positive patients with mixed cryoglobulinaemia vasculitis undergoing rituximab treatment

Rituximab in myasthenia gravis: a "to be or not to be" inhibitor of T cell function

Rheumatoid Factors in Hepatitis B and C Infections: Connecting Viruses, Autoimmunity, and Cancer

IgA rheumatoid factor as a serological predictor of poor response to tumour necrosis factor α inhibitors in rheumatoid arthritis

Serum immunoglobulin free light chain levels in systemic autoimmune rheumatic diseases

Free light chains: Eclectic multipurpose biomarker

COVID-19 and hepatic involvement: The liver as a main actor of the pandemic novel

A potential multi-target therapeutic drug for COVID-19

Table 2: Comparative analysis of biomarkers among different groups of subjects

Correlation between different biomarkers (2nd column) among the three different groups of subjects

Linear regression coefficients With CGs RF-IgA vs RF

RF-IgA =(1.35±23) + (0.33±0.11)*RF-IgM IgG1 vs RF

RF-IgG =(7.4±84.6) + (1.16±0.21)*RF-IgM IgG2 vs

) + (2.24±0.30)* RF-IgA Without CGs RF-IgA